HomeCompareRLFTD vs EQR

RLFTD vs EQR: Dividend Comparison 2026

RLFTD yields 49.02% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RLFTD wins by $334.0K in total portfolio value
10 years
RLFTD
RLFTD
● Live price
49.02%
Share price
$4.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$374.5K
Annual income
$74,708.98
Full RLFTD calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — RLFTD vs EQR

📍 RLFTD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLFTDEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLFTD + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLFTD pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLFTD
Annual income on $10K today (after 15% tax)
$4,166.67/yr
After 10yr DRIP, annual income (after tax)
$63,502.63/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, RLFTD beats the other by $60,255.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLFTD + EQR for your $10,000?

RLFTD: 50%EQR: 50%
100% EQR50/50100% RLFTD
Portfolio after 10yr
$207.5K
Annual income
$39,264.29/yr
Blended yield
18.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RLFTD
No analyst data
Altman Z
-12.4
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLFTD buys
0
EQR buys
0
No recent congressional trades found for RLFTD or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLFTDEQR
Forward yield49.02%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$374.5K$40.5K
Annual income after 10y$74,708.98$3,819.61
Total dividends collected$297.4K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: RLFTD vs EQR ($10,000, DRIP)

YearRLFTD PortfolioRLFTD Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$15,602$4,901.96$11,248$547.57+$4.4KRLFTD
2$23,842$7,147.68$12,701$666.53+$11.1KRLFTD
3$35,719$10,208.01$14,405$814.59+$21.3KRLFTD
4$52,512$14,292.70$16,413$999.84+$36.1KRLFTD
5$75,825$19,637.72$18,795$1,232.92+$57.0KRLFTD
6$107,634$26,501.16$21,639$1,527.95+$86.0KRLFTD
7$150,326$35,157.45$25,057$1,903.80+$125.3KRLFTD
8$206,739$45,889.95$29,197$2,385.87+$177.5KRLFTD
9$280,193$58,982.29$34,250$3,008.70+$245.9KRLFTD
10$374,515$74,708.98$40,467$3,819.61+$334.0KRLFTD

RLFTD vs EQR: Complete Analysis 2026

RLFTDStock

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Full RLFTD Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RLFTD vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLFTD vs SCHDRLFTD vs JEPIRLFTD vs ORLFTD vs KORLFTD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.